Mineralocorticoid Receptor Antagonist in Diabetic Kidney Disease
Article Sidebar
Main Article Content
Abstract
Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and sodium-glucose cotransporter 2 inhibitors have become the standard treatment of diabetic kidney disease (DKD). Despite the efficacy of newer drugs, the risk of progression of kidney disease, and cardiovascular morbidity and mortality remain substantial. Overactivation of mineralocorticoid receptor has been reported to play an important role in the progression of DKD and cardiovascular dysfunction through inflammation and fibrosis. Finerenone, a nonsteroidal selective mineralocorticoid receptor antagonist, may contribute to cardiorenal protection with decreased risk of hyperkalemia. Combining with the standard treatment, mineralocorticoid receptor antagonist has emerged as a promising strategy in slowing the progression of kidney disease and lowering the risk of cardiovascular disease in patients with DKD.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This article is published under CC BY-NC-ND 4.0 license, which allows for non-commercial reuse of the published paper as long as the published paper is fully attributed. Anyone can share (copy and redistribute) the material in any medium or format without having to ask permission from the author or the Nephrology Society of Thailand.
References
อรรถเกียรติ กาญจนพิบูลวงศ์, ภานุวัฒน์ คำวังสง่า, สุธิดา แก้วทา. รายงานสถานการณ์โรค NCDs พ.ศ. 2562. กรมควบคุมโรค กองโรคไม่ติดต่อ. 2563.
คณะอนุกรรมการลงทะเบียนการบำบัดทดแทนไต(TRT) สมาคมโรคไตแห่งประเทศไทย. THAILAND RENAL REPLACEMENT THERAPY : YEAR 2020. ข้อมูลการบำบัดทดแทนไตในประเทศไทย พ.ศ. 2563.
Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol. 2017;12:2032–45.
KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007;49:S42.
Sulaiman MK. Diabetic nephropathy: recent advances in pathophysiology and challenges in dietary management. Diabetology & metabolic syndrome. Sulaiman Diabetol Metab Syndr. 2019;11:7.
Kawanami D, Takashi Y, Muta Y, Oda N, Nagata D, Takahashi H, et al. Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease. Front Pharmacol. 2021;12:754239.
Nagase M. Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome. Clin Exp Nephrol. 2010;14:303–14.
Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006; 70:2116-23.
Jaisser F, Farman N. Emerging Roles of the Mineralocorticoid Receptor in Pathology: Toward New Paradigms in Clinical Pharmacology. Pharmacol Rev. 2016;68:49–75.
Barrera-Chimal J, Lima-Posada I, Bakris GL, Jaisser F. Mineralocorticoid receptor antagonists in diabetic kidney disease — mechanistic and therapeutic effects. Nat Rev Nephrol. 2022;18:56–70.
Berger S, Bleich M, Schmid W, Greger R, Schutz G. Mineralocorticoid receptor knockout mice: lessons on Na+ metabolism. Kidney Int. 2000;57:1295-8.
Shibata S, Nagase K, Yoshida S, Kawarazaki W, Kurihara H, Tanaka H, et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med. 2008;14:1370-6.
Yoshida S, Ishizawa K, Ayuzawa N, Ueda K, Takeuchi M, Kawarazaki W, et al. Local mineralocorticoid receptor activation and the role of Rac1 in obesity-related diabetic kidney disease. Nephron Exp Nephrol. 2014;126:16-24.
Liu L C Y, Schutte E, Gansevoort RT, Meer P V D, Voors AA. Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease. Expert Opin Investig Drugs. 2015;24:1123-35.
Miric G, Dallemagne C, Endre Z, Margolin S, Taylor S M, Brown L. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol. 2001;133:687-94.
Fujisawa G, Okada K, Muto S, Fujita N, Itabashi N, Kusano E, et al. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int. 2004;66: 1493-502.
Hou J. Spironolactone Add-on for Preventing or Slowing the Progression of Diabetic Nephropathy: A Meta-analysis. Clin Ther. 2015;37:2086-2103.
Lian M, Hewitson T D, Wigg Belinda, Samuel C S, Chow F, Becker G J. Long-term mineralocorticoid receptor blockade ameliorates progression of experimental diabetic renal disease. Nephrol Dial Transplant. 2012;27:906-12.
Nishiyama A, Kobori H, Konishi Y, Morikawa T, Maeda I, Okumura M, et al. Mineralocorticoid Receptor Blockade Enhances the Antiproteinuric Effect of an Angiotensin II Blocker through Inhibiting Podocyte Injury in Type 2 Diabetic Rats. J Pharmacol Exp Ther. 2010;332:1072–1080.
Mokadem ME, Hady Y A E, Aziz A. A Prospective Single-Blind Randomized Trial of Ramipril, Eplerenone and Their Combination in Type 2 Diabetic Nephropathy. Cardiorenal Med. 2020;10:392-401.
Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA. 2015;314:884-94.
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383:2219–29.
Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021; 385:2252-2263
Wada T, Inagaki M, Yoshinari T, Terata R, Totsuka N, Gotou M, et al. Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose–response study and open-label extension study. Clin Exp Nephrol. 2021;25:120–30.
Ito S, Kashihara N, Shikata K, Nangaku M, Wada T, Okuda Y, et al. Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial. CJASN. 2020;15:1715–27.
Zuo C, Xu G. Efficacy and safety of mineralocorticoid receptor antagonists with ACEI/ARB treatment for diabetic nephropathy: A meta-analysis. Int J Clin Pract. 2019; 29:e13413.
Schork A, Saynisch J, Vosseler A, Jaghutriz B A, Heyne N, Peter A, et al. Effect of SGLT2 inhibitors on body composition, fluid status and renin– angiotensin– aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy. Cardiovasc Diabetol. 2019;18:46.
Pitt B, Anker S D, Bohm M, Gheorghiade M, Kober L, Krum H, et al. Rationale and design of Mineralocorticoid Receptor antagonist Tolerability of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. Eur J Heart Fail. 2015;17:224-32.
Yang C-T, Kor C-T, Hsieh Y-P. Long-Term Effects of Spironolactone on Kidney Function and Hyperkalemia-Associated Hospitalization in Patients with Chronic Kidney Disease. J Clin Med. 2018;7:459.
Quach K, Lvtvyn L, Baigent C, Bueti J, Garg A X, Hawley, et al. The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis. Am J Kidney Dis. 2016;68:591-598.
Agarwal R, Rossignol P, Romero A, Garza D, Mayo M R, Warren S, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomized, double-blind, placebo-controlled trial. Lancet. 2019;394: 1540-1550.
Higashikawa T, Ito T, Mizuno T, Ishigami K, Kohori M, Mae K, et al. Effects of Tofogliflozin on Cardiac Function in Elderly Patients With Diabetes Mellitus. J Clin Med Res. 2020;12: 165-171.